Table 2. Pretreatment, Posttreatment, Percentage Change, and Absolute Change of Circulating Hormone and Lipid Levels by Study Arm.
Biomarker | Median (IQR) | P value change, adjusteda | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Exemestane, 25 mg, QD (n = 55) | Exemestane, 25 mg, TIW (n = 56) | Exemestane, 25 mg, QW (n = 60) | ||||||||||||
Pretreatment | Posttreatment | % Change | Absolute change | Pretreatment | Posttreatment | % Change | Absolute change | Pretreatment | Posttreatment | % Change | Absolute change | QD vs TIW | QD vs QW | |
Estrone, pmol/L | ||||||||||||||
Solid-phase extraction | 104.3 (73.8 to 141.0) | 7.0 (1.3 to 13.4) | −93 (−98 to −88) | −95.5 (−126.8 to −65.9) | 99.4 (69.4 to 137.6) | 9.1 (4.6 to 16.1) | −89 (−96 to −83) | −80.0 (−119.7 to −60.4) | 92.2 (66.7 to 122.8) | 26.1 (18.5 to 43.1) | −73 (−81 to −52) | −61.7 (−92.2 to −36.4) | .42 | .004 |
Liquid-liquid extraction | 101.0 (69.6 to 143.0) | 1.6 (0.90 to 2.9) | −99 (−99 to −98) | −97.6 (−135.8 to −67.1) | 96.2 (72.1 to 147.5) | 4.3 (2.5 to 6.6) | −96 (−97 to −93) | −88.4 (−125.1 to −67.2) | 93.4 (69.5 to 132.0) | 21.8 (12.8 to 34.2) | −78 (−85 to −62) | −65.2 (−103.3 to −43.9) | .29 | .004 |
Total | 294.7 (182.6 to 451.4) | 12.5 (12.5 to 12.5) | −95 (−97 to −91) | −267.4 (−437.3 to −167.6) | 302.2 (160.0 to 429.9) | 12.5 (12.5 to 12.5) | −94 (−96 to −90) | −286.5 (−397. 8 to 145.6) | 246.1 (164.0 to 362.1) | 61.9 (32.3 to 92.6) | −76 (−85 to −63) | −179.6 (−273.4 to −117.1) | .74 | .01 |
Estrone sulfate, pmol/L | 581.9 (363.6 to 918.9) | 13.8 (13.8 to 35.7) | −96 (−98 to −94) | −568.1 (−853.7 to −349.8) | 625.8 (324.7 to 955.6) | 13.8 (13.8 to 55.2) | −95 (−97 to −92) | −546.6 (−775.4 to −301.4) | 452.3 (315.1 to 710.6) | 124.8 (55.7 to 193.9) | −75 (−83 to −64) | −322.7 (−518.8 to −222.3) | .39 | .15 |
Androstenedione, nmol/L | 1.5 (1.0 to 1.9) | 1.4 (1.10 to 1.90) | 0 (−18 to 18) | 0.00 (−0.30 to 0.20) | 1.7 (1.1 to 2.5) | 1.8 (1.1 to 2.6) | 11 (−20 to 30) | 0.20 (−0.20 to 0.50) | 1.4 (1.1 to 2.0) | 1.6 (1.1 to 2.0) | 11 (−14 to 43) | 0.10 (−0.20 to 0.60) | .21 | .46 |
Testosterone, nmol/L | 0.60 (0.40 to 0.90) | 0.45 (0.30 to 0.80) | −19 (−33 to 0) | −0.10 (−0.20 to 0) | 0.70 (0.40 to 1.1) | 0.50 (0.30 to 0.90) | 0 (−25 to 0) | 0.00 (−0.20 to 0.00) | 0.60 (0.40 to 0.90) | 0.60 (0.40 to 0.80) | 0 (−20 to 18) | 0.0 (−0.10 to 0.10) | .72 | .30 |
SHBG, nmol/L | 53.4 (39.1 to 64.0) | 36.0 (27.6 to 50.3) | −29 (−36 to −17) | −12.8 (−20.7 to −8.7) | 47.9 (36.6 to 65.1) | 40.0 (30.3 to 56.7) | −15 (−23 to −7) | −7.0 (−11.4 to −2.9) | 50.1 (31.9 to 67.8) | 45.8 (26.4 to 60.9) | −6 (−17 to 1) | −2.3 (−6.0 to 0.40) | .01 | .004 |
Cholesterol, mg/dL | ||||||||||||||
HDL | 62 (55 to 72) | 56 (46 to 63) | −14 (−21 to −3) | −10 (−13 to −2) | 59 (48 to 71) | 57 (46 to 65) | −5 (−13 to 4) | −4 (−9 to 2) | 57 (50 to 67) | 57 (50 to 69) | −1 (−9 to 4) | 1 (−22 to 14) | .05 | .06 |
Total | 205 (181 to 233) | 201 (175 to 222) | −6 (−17 to 3) | −11 (−35 to 7) | 208 (182 to 226) | 195 (173 to 210) | −6 (−11 to 1) | −11 (24 to 2) | 220 (200 to 247) | 220 (195 to 245) | 0 (−8 to 6) | −1 (−5 to 2) | .50 | .05 |
Abbreviations: HDL, high-density lipoprotein; QD, once daily; QW, once weekly; SHBG, sex hormone–binding globulin; TIW, 3 times weekly.
SI conversion factor: To convert HDL to mmol/L, multiply by 0.0259.
P values from analysis of covariance models on absolute changes in time, adjusted for baseline values, age, and body mass index. All P values were also adjusted for multiple testing.